Lavipharm has been growing earnings at an average annual rate of 29.5%, while the Pharmaceuticals industry saw earnings growing at 8.8% annually. Revenues have been growing at an average rate of 8.9% per year. Lavipharm's return on equity is 9%, and it has net margins of 8.1%.
Key information
29.52%
Earnings growth rate
-33.95%
EPS growth rate
Pharmaceuticals Industry Growth
7.33%
Revenue growth rate
8.94%
Return on equity
8.95%
Net Margin
8.06%
Next Earnings Update
28 May 2026
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Lavipharm makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
DB:BXA0 Revenue, expenses and earnings (EUR Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
63
5
23
0
30 Sep 25
55
2
21
1
30 Jun 25
55
2
21
1
31 Mar 25
53
9
26
1
31 Dec 24
53
9
21
1
30 Sep 24
46
9
18
0
30 Jun 24
47
8
19
0
31 Mar 24
52
2
19
0
31 Dec 23
48
2
18
0
30 Sep 23
54
0
16
1
30 Jun 23
44
1
16
1
31 Mar 23
49
1
16
1
31 Dec 22
39
1
15
1
30 Sep 22
43
2
4
0
30 Jun 22
41
1
15
1
31 Mar 22
41
1
12
1
31 Dec 21
40
2
15
1
30 Sep 21
39
2
15
1
30 Jun 21
39
3
14
1
31 Mar 21
38
2
14
1
31 Dec 20
38
2
14
1
30 Sep 20
37
4
14
1
30 Jun 20
36
7
14
1
31 Mar 20
35
6
14
1
31 Dec 19
34
5
14
1
30 Sep 19
34
3
14
1
30 Jun 19
34
1
14
1
31 Mar 19
34
1
15
1
31 Dec 18
34
1
15
1
30 Sep 18
33
0
16
1
30 Jun 18
32
-1
16
1
31 Mar 18
32
6
16
1
31 Dec 17
32
13
15
2
30 Sep 17
32
11
17
2
30 Jun 17
32
10
18
2
31 Mar 17
32
7
18
2
31 Dec 16
31
4
18
3
30 Sep 16
31
4
18
3
30 Jun 16
28
4
15
3
31 Mar 16
27
-2
15
3
31 Dec 15
26
-7
15
3
30 Sep 15
27
-9
15
4
30 Jun 15
29
-9
17
4
Quality Earnings: BXA0 has high quality earnings.
Growing Profit Margin: BXA0's current net profit margins (8.1%) are lower than last year (16.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BXA0's earnings have grown significantly by 29.5% per year over the past 5 years.
Accelerating Growth: BXA0's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BXA0 had negative earnings growth (-41.8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (16.1%).
Return on Equity
High ROE: BXA0's Return on Equity (9%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/05/22 14:07
End of Day Share Price
2026/05/22 00:00
Earnings
2025/12/31
Annual Earnings
2025/12/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lavipharm S.A. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.